Rhovac board member resigns due to health reasons

RhoVac AB (publ) announces today, October 18^th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons.

Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I would like to give a warm thank you to Anders for his decisive contributions in various roles in the company throughout the years. He has been an inspiration to all of us and it is regrettable but completely understandable that Anders is now forced to focus on his health and family and thus leaves the board's work".

For further information, please contact:

Gunnar Gårdemyr – Chairman of the board
RhoVac AB
Telephone +46 730 837779
E-mail: info@rhovac.com

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company's auspices, the basic development steps for the drug candidate onilcamotide (formerly RV001) were undertaken. In 2015, the Swedish RhoVac AB was formed, which is now the head office, and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2019, patient recruitment began for a larger phase IIb clinical study that included approximately 180 patients with prostate cancer. The Top Line results were presented in May 2022. Additional data are currently being evaluated. RhoVac is listed on the Spotlight Stockmarket. The stock trades under the ticker RHOVAC. More information is available at www.rhovac.com.

---